Małgorzata Jurczyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Małgorzata Jurczyk has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Glapa
Wroclaw Medical University
4 shared publications - Anna Wojdas
Wroclaw Medical University
4 shared publications - Hanna Ludwisiak
Wroclaw Medical University
4 shared publications - Julia Owsik
Wroclaw Medical University
4 shared publications - Maja Cwalina
Wroclaw Medical University
4 shared publications - Małgorzata Dorożalska
Wroclaw Medical University
4 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 79, 76662
Exercise Therapy in the Management of Chronic Low Back Pain: Current Evidence and Practical Implications – A Narrative Review
Background: Chronic low back pain (CLBP) is a multifactorial condition influenced by physical, psychological, and social factors. Exercise therapy is a core element of conservative management, yet it encompasses highly heterogeneous interventions. Aim: This narrative review summarizes current evidence on the effectiveness and safety of exercise therapy for CLBP, focusing on exercise modalities, optimal doses, individualization, special populations, delivery methods, and practical implications. Material and Methods: A narrative literature review was conducted primarily through PubMed and completed in August 2026. The search was limited to studies published in the preceding five years involving adult participants with CLBP, including systematic reviews, meta-analyses, and randomized controlled trials. Results: Exercise therapy produces a clinically important reduction in pain intensity (approx. 15 points on a 0–100 scale) and a smaller improvement in functional disability compared to no treatment or placebo. No single exercise modality has demonstrated consistent superiority. Regular participation (15–30 minutes per session, three times per week, programs lasting at least 16 weeks) is favorable. Benefits are most evident versus inactive controls and diminish when compared with other active treatments. Adherence, individualization, and continued physical activity are key determinants of success. Exercise is generally safe, with mild, transient musculoskeletal symptoms being the most common adverse effects. Conclusions: Exercise therapy is an effective, adaptable, and safe non-pharmacological intervention for CLBP. Outcomes depend less on the specific modality than on adequate dosage, sustained adherence, and a patient-centred approach integrating individual preferences, functional goals, and psychological strategies.
- 11 November 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 79, 76662
Open AccessExercise Therapy in the Management of Chronic Low Back Pain: Current Evidence and Practical Implications – A Narrative Review
Background: Chronic low back pain (CLBP) is a multifactorial condition influenced by physical, psychological, and social factors. Exercise therapy is a core element of conservative management, yet it encompasses highly heterogeneous interventions. Aim: This narrative review summarizes current evidence on the effectiveness and safety of exercise therapy for CLBP, focusing on exercise modalities, optimal doses, individualization, special populations, delivery methods, and practical implications. Material and Methods: A narrative literature review was conducted primarily through PubMed and completed in August 2026. The search was limited to studies published in the preceding five years involving adult participants with CLBP, including systematic reviews, meta-analyses, and randomized controlled trials. Results: Exercise therapy produces a clinically important reduction in pain intensity (approx. 15 points on a 0–100 scale) and a smaller improvement in functional disability compared to no treatment or placebo. No single exercise modality has demonstrated consistent superiority. Regular participation (15–30 minutes per session, three times per week, programs lasting at least 16 weeks) is favorable. Benefits are most evident versus inactive controls and diminish when compared with other active treatments. Adherence, individualization, and continued physical activity are key determinants of success. Exercise is generally safe, with mild, transient musculoskeletal symptoms being the most common adverse effects. Conclusions: Exercise therapy is an effective, adaptable, and safe non-pharmacological intervention for CLBP. Outcomes depend less on the specific modality than on adequate dosage, sustained adherence, and a patient-centred approach integrating individual preferences, functional goals, and psychological strategies.
- Open Access
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76161
The effects of high intensity interval training (HIIT) on insulin sensitivity and metabolic health in adults with prediabetes
Background. Prediabetes elevates lifetime risk of type 2 diabetes and cardiovascular disease. Moderate-intensity continuous training (MICT) improves metabolic health but is limited by time demands. High-intensity interval training (HIIT) is a time-efficient alternative that can match or exceed MICT benefits for insulin sensitivity and glycemic control, yet optimal protocols remain unclear. Aim. To evaluate the effects of HIIT on insulin sensitivity and metabolic health in adults with prediabetes. Material and methods. PubMed, Scopus and Google Scholar were searched for English-language peer-reviewed studies (2015–2026) on HIIT and insulin sensitivity or metabolic outcomes in adults with prediabetes. Eligible randomised controlled trials, controlled trials, observational studies and reviews were screened by title/abstract and full text after duplicate removal; reference lists were also hand-searched. Results. HIIT improved muscle and whole-body insulin sensitivity, reduced fasting glucose and HbA1c, and increased VO₂max, often comparably to MICT despite lower time commitment. Higher-volume protocols yielded greater HbA1c reductions; greater volume also strengthened benefits for fasting glucose, insulin and HOMA-IR. Combined HIIT plus diet produced the best BMI outcomes, while clamp-derived insulin sensitivity improvements partly depended on ≥3 % weight loss. Superiority over MICT varied by outcome and protocol. Conclusions. HIIT delivers meaningful gains in insulin sensitivity and metabolic health that are frequently comparable to MICT with substantially less time. Larger standardised trials are needed to define optimal, individualised prescriptions for type 2 diabetes prevention.
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76161
Open AccessThe effects of high intensity interval training (HIIT) on insulin sensitivity and metabolic health in adults with prediabetes
Background. Prediabetes elevates lifetime risk of type 2 diabetes and cardiovascular disease. Moderate-intensity continuous training (MICT) improves metabolic health but is limited by time demands. High-intensity interval training (HIIT) is a time-efficient alternative that can match or exceed MICT benefits for insulin sensitivity and glycemic control, yet optimal protocols remain unclear. Aim. To evaluate the effects of HIIT on insulin sensitivity and metabolic health in adults with prediabetes. Material and methods. PubMed, Scopus and Google Scholar were searched for English-language peer-reviewed studies (2015–2026) on HIIT and insulin sensitivity or metabolic outcomes in adults with prediabetes. Eligible randomised controlled trials, controlled trials, observational studies and reviews were screened by title/abstract and full text after duplicate removal; reference lists were also hand-searched. Results. HIIT improved muscle and whole-body insulin sensitivity, reduced fasting glucose and HbA1c, and increased VO₂max, often comparably to MICT despite lower time commitment. Higher-volume protocols yielded greater HbA1c reductions; greater volume also strengthened benefits for fasting glucose, insulin and HOMA-IR. Combined HIIT plus diet produced the best BMI outcomes, while clamp-derived insulin sensitivity improvements partly depended on ≥3 % weight loss. Superiority over MICT varied by outcome and protocol. Conclusions. HIIT delivers meaningful gains in insulin sensitivity and metabolic health that are frequently comparable to MICT with substantially less time. Larger standardised trials are needed to define optimal, individualised prescriptions for type 2 diabetes prevention.
- Open Access
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76169
GLP-1 Receptor Agonists Beyond Metabolic Control: Cardiovascular Benefits, Renal Protection, Neurological Effects and Socioeconomic Implications of Widespread Use.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used in type 2 diabetes and obesity. Evidence suggests additional cardiovascular, renal, and neurological effects, with important socioeconomic implications. Aim: To evaluate GLP-1 RA effects beyond metabolic control, focusing on cardiovascular, renal, neurological, physical activity, and socioeconomic outcomes. Material and methods: PubMed, Embase, and Scopus were searched for studies published from 2022 to 2026. Adult human studies assessing cardiovascular, renal, cerebrovascular, neurological or socioeconomic outcomes were included. After screening, 39 publications were qualitatively synthesized. Results: GLP-1 RAs were associated with reduced major adverse cardiovascular events, cardiovascular mortality, myocardial infarction, and selected heart-failure outcomes. Semaglutide reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease. Neurological effects included reduced cerebrovascular events and intracranial pressure, while evidence regarding cognition and neurodegenerative disorders remained heterogeneous. Conclusions: GLP-1 RAs exert multisystem effects beyond metabolic control, including cardiovascular and renal protection and neurological effects. Their expanding use may provide substantial health benefits but also raises concerns regarding treatment costs and socioeconomic disparities in access.
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76169
Open AccessGLP-1 Receptor Agonists Beyond Metabolic Control: Cardiovascular Benefits, Renal Protection, Neurological Effects and Socioeconomic Implications of Widespread Use.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used in type 2 diabetes and obesity. Evidence suggests additional cardiovascular, renal, and neurological effects, with important socioeconomic implications. Aim: To evaluate GLP-1 RA effects beyond metabolic control, focusing on cardiovascular, renal, neurological, physical activity, and socioeconomic outcomes. Material and methods: PubMed, Embase, and Scopus were searched for studies published from 2022 to 2026. Adult human studies assessing cardiovascular, renal, cerebrovascular, neurological or socioeconomic outcomes were included. After screening, 39 publications were qualitatively synthesized. Results: GLP-1 RAs were associated with reduced major adverse cardiovascular events, cardiovascular mortality, myocardial infarction, and selected heart-failure outcomes. Semaglutide reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease. Neurological effects included reduced cerebrovascular events and intracranial pressure, while evidence regarding cognition and neurodegenerative disorders remained heterogeneous. Conclusions: GLP-1 RAs exert multisystem effects beyond metabolic control, including cardiovascular and renal protection and neurological effects. Their expanding use may provide substantial health benefits but also raises concerns regarding treatment costs and socioeconomic disparities in access.
- Open Access
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76187
Treatments burden in adults with end stage renal disease receiving haemodialysis impact on medication adherence and health related quality of life.
Background: Haemodialysis imposes substantial treatment burden, affecting medication adherence and health-related quality of life (HRQoL). This study assessed treatment burden and its associations with these outcomes in adults receiving haemodialysis. Aim: To assess treatment burden in adults with end-stage renal disease (ESRD) receiving haemodialysis and examine its associations with medication adherence and HRQoL. Materials and Methods: A systematic search of PubMed, Embase and Scopus was conducted for publications from 2000 to 2026. After deduplication of 290 records, manual screening yielded 37 eligible studies — restricted to systematic reviews, meta-analyses, clinical trials, and Mendelian randomisation analyses involving adults (≥18 years). Results: Treatment burden in haemodialysis patients is multidimensional, encompassing high pill burden, time demands and significant psychological distress. Non-adherence rates reached up to 50%, driven by regimen complexity, depression, and caregiver strain. Physical HRQoL was more severely impaired than mental HRQoL, with fatigue and musculoskeletal symptoms as primary drivers. Longer dialysis vintage correlated with progressive symptom worsening Conclusions: Treatment burden in ESRD patients undergoing haemodialysis significantly impairs medication adherence and HRQoL, particularly in physical domains. Integrated, patient-centred strategies, including regimen simplification and psychosocial support, are needed.
- 2 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76187
Open AccessTreatments burden in adults with end stage renal disease receiving haemodialysis impact on medication adherence and health related quality of life.
Background: Haemodialysis imposes substantial treatment burden, affecting medication adherence and health-related quality of life (HRQoL). This study assessed treatment burden and its associations with these outcomes in adults receiving haemodialysis. Aim: To assess treatment burden in adults with end-stage renal disease (ESRD) receiving haemodialysis and examine its associations with medication adherence and HRQoL. Materials and Methods: A systematic search of PubMed, Embase and Scopus was conducted for publications from 2000 to 2026. After deduplication of 290 records, manual screening yielded 37 eligible studies — restricted to systematic reviews, meta-analyses, clinical trials, and Mendelian randomisation analyses involving adults (≥18 years). Results: Treatment burden in haemodialysis patients is multidimensional, encompassing high pill burden, time demands and significant psychological distress. Non-adherence rates reached up to 50%, driven by regimen complexity, depression, and caregiver strain. Physical HRQoL was more severely impaired than mental HRQoL, with fatigue and musculoskeletal symptoms as primary drivers. Longer dialysis vintage correlated with progressive symptom worsening Conclusions: Treatment burden in ESRD patients undergoing haemodialysis significantly impairs medication adherence and HRQoL, particularly in physical domains. Integrated, patient-centred strategies, including regimen simplification and psychosocial support, are needed.